Carmell Therapeutics Corporation is a privately-owned biotechnology company focused on the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs). These PBMs contain a concentration of natural regenerative factors that promote healing, reduce complications, and lead to healthcare savings.
Carmell’s first PBM product, Bone Healing Accelerant, has clinically demonstrated safety and efficacy in accelerating bone and soft tissue healing and reducing infections when treating open bone fractures. While this first indication represents a huge opportunity in itself, the company plans to address the larger orthopedic markets of bone and soft tissue healing for spine procedures, joint replacements, sports injuries (i.e. meniscus/ACL & shoulder repairs), and spinal fusion.
Carmell’s second PBM product, Tissue Healing Accelerant, will address an unmet need in managing surgical site healing and chronic wounds. Improving healing over the standard of care will result in a reduction in costs to both the hospital and patient.
Future products will be focused on leveraging Carmell’s technology to address large unmet needs in the areas of Gastrointestinal (GI) leak sealing, dermatology applications, and beyond.